Jubilant Pharma Gets USFDA VAI Classification for Roorkee Unit
By Rediff Money Desk, NEWDELHI Apr 17, 2024 17:07
Jubilant Pharma's Roorkee unit receives a Voluntary Action Indicated (VAI) classification from the USFDA, indicating acceptable compliance with cGMP.

New Delhi, Apr 17 (PTI) Jubilant Pharma on Wednesday said the US health regulator has decided that the inspection classification of its subsidiary's Roorkee-based plant is voluntary action indicated (VAI).
Jubilant Pharmova, a wholly-owned subsidiary of the company, has received a communication from the US Food and Drug Administration (USFDA) that the facility has been classified as VAI pursuant to inspection from January 25 to February 2, 2024, it said in a regulatory filing.
As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.
"Based on this inspection and the USFDA VAI classification, the facility is considered to be in acceptable state of compliance with regard to current good manufacturing practices (cGMP)," it added.
With this, the FDA has concluded that this inspection is closed, Jubilant Pharma said.
Jubilant Pharmova, a wholly-owned subsidiary of the company, has received a communication from the US Food and Drug Administration (USFDA) that the facility has been classified as VAI pursuant to inspection from January 25 to February 2, 2024, it said in a regulatory filing.
As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.
"Based on this inspection and the USFDA VAI classification, the facility is considered to be in acceptable state of compliance with regard to current good manufacturing practices (cGMP)," it added.
With this, the FDA has concluded that this inspection is closed, Jubilant Pharma said.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.21 ( -5.09)
- 50736618
- AvanceTechnologies
- 0.64 ( -5.88)
- 23261214
- Srestha Finvest
- 0.63 ( -3.08)
- 17968849
- Vakrangee
- 16.71 (+ 4.96)
- 14316214
- G G Engineering
- 1.11 ( -4.31)
- 13184477
MORE NEWS
Mahindra Lifespace Raises Rs 1,500 cr via...
Mahindra Lifespace Developers plans to raise up to Rs 1,500 crore through a rights...

Livestock Productivity & Disease Control: Govt...
India's Minister of State for Fisheries, Animal Husbandry & Dairying highlights the...
Manaksia Coated Metals Q3 Profit Up 23% - PTI
Manaksia Coated Metals reported a 23% increase in consolidated net profit to Rs 5.07...